Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer

WILMINGTON, Del.--(Healthcare Sales &Marketing Network)--Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of ... Biopharmaceuticals, OncologyIncyte, JANUS 1, ruxolitinib, capecitabine, pancreatic cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Kang M, Li Y, Zhu S, Zhang S, Guo S, Li P Abstract In recent years, microRNA-193b (miR-193b) is regarded as a tumor suppressor in the development and progression of various cancers. Several studies have indicated that KRAS could be regulated by miR-193b in pancreatic cancer cells. However, the function of miR-193b in human esophageal squamous cell carcinoma has not been explored intensively thus far. Herein, the relationship between miR-193b and KRAS was mainly explored in esophageal squamous cell carcinoma cells. In the present study, the expression levels of miR-193b and KRAS were assessed in both human ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Buck E, Sprick M, Gaida MM, Grüllich C, Weber TF, Herpel E, Bruckner T, Koschny R Abstract Recently, a tumor-autonomous cytochrome P450 (CYP)-3A5-mediated resistance to cancer therapy has been demonstrated in pancreatic ductal adenocarcinoma. Expression of CYP3A5, which is involved in the degradation of irinotecan, has also been reported in colorectal cancer (CRC). The aim of the present study was to analyze CYP3A5 expression in the normal colon, colon adenoma, CRC and normal tissues, as well as to examine whether CYP3A5 expression in CRC has an impact on tumor response to irinotecan treatment. Immuno...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: He Y, Liu Y, Gong J, Liu C, Zhang H, Wu H Abstract Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with a high degree of malignancy that is difficult to diagnose and treat. The present study integrated PDAC cohort profile datasets to identify key candidate genes and pathways involved in the pathogenesis of the disease. The expression profiles of GSE28735 included 45 PDCA and matching pairs of adjacent non-tumor tissue. Differentially expressed genes (DEGs) were sorted and candidate genes and pathway enrichment were analyzed. A DEG-associated protein-protein interaction (PPI) network was constr...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Date: Friday, 03 22, 2019; Speaker: Christine Campo Alewine, MD PhD, Investigator, NCI, NIH; Building 37, Rooms 6041 /6107 ; 6th floor conference room
Source: NIH Calendar of Events - Category: American Health Source Type: events
By HANS DUVEFELT MD Jeanette Brown had lost twenty pounds, and she was worried. “I’m not trying,” she told me at her regular diabetes visit as I pored over her lab results. What I saw sent a chill down my spine: A normal weight, diet controlled diabetic for many years, her glycosylated hemoglobin had jumped from 6.9 to 9.3 in three months while losing that much weight. That is exactly what happened to my mother some years ago, before she was diagnosed with the pancreatic cancer that took her life in less than two years. Jeanette had a normal physical exam and all her bloodwork except for t...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Medicare Hans Duvefelt Managed Care Source Type: blogs
Abstract KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer. Here, we developed a novel anchor-like DNA (alDNA) electrochemical sensor for the detection of KRAS point mutation level (the concentration ratio of the specific KRAS point mutant DNA (M-DNA) to the total DNA (t-DNA) of both mutant and wild-type DNAs carrying the same allele). Compared to those conventional ligation-based DNA sensors, the proposed alDNA sensor achieved the one-step capture of both wild-type and mutant DNA, and the subseq...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
Conditions:   Breast Cancer;   Prostate Cancer;   Pancreatic Cancer;   Acute Myelogenous Leukemia Interventions:   Procedure: Biopsy;   Drug: ABIRATERONE;   Drug: ENZALUTAMIDE;   Drug: VENETOCLAX;   Drug: PALBOCICLIB;   Drug: All-trans Retinoic Acid;   Drug: BORTEZOMIB;   Drug: CABAZITAXEL;   Drug: OXALIPLATIN;   Drug: FLUOROURACIL;   Drug: FOLINIC ACID;   Drug: CARBOPLATIN;   Drug : PANOBINOSTAT;   Drug: VORINOSTAT;   Dr...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Ribatti Angiogenesis is a crucial event in tumor development and progression, occurring by different mechanisms and it is driven by pro- and anti-angiogenic molecules. Pancreatic cancer vascularization is characterized by a high microvascular density, impaired microvessel integrity and poor perfused vessels with heterogeneous distribution. In this review article, after a brief introduction on pancreatic cancer classification and on angiogenesis mechanisms involved in its progression, the pre-clinical and clinical trials conducted in pancreatic cancer treatment using anti-angiogenic inhibitors will be described. Finall...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study examined the impact of a positive resection margin (R1) on locoregional recurrence (LRR) and overall survival (OS); and also aimed to identified tumour characteristics and/or technical factors associated with a positive resection margin in patients with PDAC. METHODS: Patients scheduled for pancreatic resection for PDAC between 2006 and 2016 were identified from an institutional database. The effect of resection margin status, patient characteristics and tumour characteristics on LRR, distant metastasis and OS was assessed. RESULTS: A total of 322 patients underwent pancreatectomy for PDAC. A positive ...
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
AbstractPancreatectomy might confer a survival benefit in patients with metastatic tumors of the pancreas (MTPs); however, the optimal treatment for MTP has not been established. We reviewed six patients with MTP undergoing pancreatectomy and discussed the clinical features, surgical treatment, and survival. The sites of primary cancer included renal cell carcinoma (RCC) (n = 5; 83.3%) and rectal cancer (n = 1; 16.7%). The median interval between the resection of the primary site and the development of MTP was 157 months (range, 16–180 months). Three (60.0%) of the five cases of ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study | Xeloda